Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

Mahgoub,T.; Eustace,A. J.; Collins,D. M.; Walsh,N.; O'Donovan,N.; Crown,J.

doi:10.3892/ijo.2015.3097

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

Authors:
- T. Mahgoub
- A. J. Eustace
- D. M. Collins
- N. Walsh
- N. O'Donovan
- J. Crown
View Affiliations

Affiliations: National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland, Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland
Published online on: July 21, 2015 https://doi.org/10.3892/ijo.2015.3097
Pages: 900-908
Copyright: © Mahgoub et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective of the present study was to identify novel therapeutic targets for metastatic melanoma. A library of 160 well-characterised and potent protein kinase inhibitors was screened in the BRAF mutant cell line Sk-Mel-28, and the NRAS mutant Sk-Mel-2, using proliferation assays. Of the 160 inhibitors tested, 20 achieved >50% growth inhibition in both cell lines. Six of the 20 were cyclin dependent kinase (CDK) inhibitors, including two CDK4 inhibitors. Fascaplysin, a synthetic CDK4 inhibitor, was further tested in 8 melanoma cell lines. The concentration of fascaplysin required to inhibit growth by 50% (IC50 value) ranged from 0.03 to 0.22 µM. Fascaplysin also inhibited clonogenic growth and induced apoptosis. Sensitivity to PD0332991, a therapeutic CDK4/6 inhibitor was also evaluated in the melanoma cell lines. PD0332991 IC50 values ranged from 0.13 to 2.29 µM. Similar to fascaplysin, PD0332991 inhibited clonogenic growth of melanoma cells and induced apoptosis. Higher levels of CDK4 protein correlated with lower sensitivity to PD0332991 in the cell lines. Combined treatment with PD0332991 and the BRAF inhibitor PLX4032, showed additive anti-proliferative effects in the BRAF mutant cell line Malme-3M. In summary, targeting CDK4 inhibits growth and induces apoptosis in melanoma cells in vitro, suggesting that CDK4 may be a rational therapeutic target for metastatic melanoma.

View Figures

View References

1	Bhatia S, Tykodi SS, Lee SM and Thompson JA: Systemic therapy of metastatic melanoma: On the road to cure. Oncology (Williston Park). 29:126–135. 2015.
2	Dummer R and Flaherty KT: Resistance patterns with tyrosine kinase inhibitors in melanoma: New insights. Curr Opin Oncol. 24:150–154. 2012. View Article : Google Scholar : PubMed/NCBI
3	Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hunter T and Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem. 54:897–930. 1985. View Article : Google Scholar : PubMed/NCBI
5	Cicenas J and Valius M: The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 137:1409–1418. 2011. View Article : Google Scholar : PubMed/NCBI
6	Diaz-Padilla I, Siu LL and Duran I: Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs. 27:586–594. 2009. View Article : Google Scholar : PubMed/NCBI
7	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
8	Malumbres M and Barbacid M: Cell cycle kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sharpless E and Chin L: The INK4a/ARF locus and melanoma. Oncogene. 22:3092–3098. 2003. View Article : Google Scholar : PubMed/NCBI
11	Jonsson A, Tuominen R, Grafström E, Hansson J and Egyhazi S: High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol. 130:2809–2817. 2010. View Article : Google Scholar : PubMed/NCBI
12	Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 7:2876–2883. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sausville EA: Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 8(Suppl): S32–S37. 2002. View Article : Google Scholar : PubMed/NCBI
14	Lee JH, Choi JW and Kim YS: Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol. 164:776–784. 2011. View Article : Google Scholar
15	Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G and Herlyn M: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 10:2986–3001. 2005. View Article : Google Scholar : PubMed/NCBI
16	Harper JW and Adams PD: Cyclin-dependent kinases. Chem Rev. 101:2511–2526. 2001. View Article : Google Scholar : PubMed/NCBI
17	Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID and Fountain JW: Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer. 22:157–163. 1998. View Article : Google Scholar : PubMed/NCBI
18	Ibrahim N and Haluska FG: Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol. 4:551–579. 2009. View Article : Google Scholar : PubMed/NCBI
19	Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med. 353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
20	Roll DM, Ireland CM, Lu HSM and Clardy J: Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis Sp. J Org Chem. 53:3276–3278. 1988. View Article : Google Scholar
21	Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H and Chaudhuri B: Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Commun. 275:877–884. 2000. View Article : Google Scholar : PubMed/NCBI
22	Shafiq MI, Steinbrecher T and Schmid R: Fascaplysin as a specific inhibitor for CDK4: Insights from molecular modelling. PLoS One. 7:e426122012. View Article : Google Scholar : PubMed/NCBI
23	Yan X, Chen H, Lu X, Wang F, Xu W, Jin H and Zhu P: Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model. Eur J Pharm Sci. 43:251–259. 2011. View Article : Google Scholar : PubMed/NCBI
24	Segraves NL, Robinson SJ, Garcia D, Said SA, Fu X, Schmitz FJ, Pietraszkiewicz H, Valeriote FA and Crews P: Comparison of fascaplysin and related alkaloids: A study of structures, cytotoxicities, and sources. J Nat Prod. 67:783–792. 2004. View Article : Google Scholar : PubMed/NCBI
25	McArthur AG, Young RJ, Sheppard KE, Mar V, Waldeck K, Fox SB, Kelleher FC, Liu W, Dobrovic A, Pearson R, et al: Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD0332991 in melanoma. J Clin Oncol. 30:85202012.
26	Herlyn M, Balaban G, Bennicelli J, Guerry D IV, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC, et al: Primary melanoma cells of the vertical growth phase: Similarities to metastatic cells. J Natl Cancer Inst. 74:283–289. 1985.PubMed/NCBI
27	Lu XL, Zheng YL, Chen HM, Yan XJ, Wang F and Xu WF: Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Yao Xue Xue Bao. 44:980–986. 2009.(In Chinese).
28	Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
29	Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar : PubMed/NCBI
30	Sanchez-Martinez C, Gelbert L, Shannon H, De Dios A, Staton BA, Ajamie RT, Sawada G, Wishart GN and Raub TJ: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol Cancer Ther. 10:B2342011. View Article : Google Scholar
31	Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, et al: Membrane transport proteins in human melanoma: Associations with tumour aggressiveness and metastasis. Br J Cancer. 102:1157–1162. 2010. View Article : Google Scholar : PubMed/NCBI
32	Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, et al: Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 27:590–600. 2014. View Article : Google Scholar : PubMed/NCBI
33	Hörmann A, Chaudhuri B and Fretz H: DNA binding properties of the marine sponge pigment fascaplysin. Bioorg Med Chem. 9:917–921. 2001. View Article : Google Scholar : PubMed/NCBI
34	Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, et al: Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 104:1673–1679. 2012. View Article : Google Scholar : PubMed/NCBI